Close Menu

NEW YORK – Drugmaker Oncoceutics said Monday that the National Brain Tumor Society will provide $200,000 to support an upcoming Phase II trial of ONC201 in a molecularly defined subset of glioma patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.